Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

NCT05669599 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

592

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Overweight
Type 2 Diabetes Mellitus

Interventions

BIOLOGICAL: Maridebart Cafraglutide
DRUG: Placebo

Sponsor

Amgen